Which coagulation factor is primarily associated with treatment in patients with von Willebrand’s disease?

In patients with von Willebrand’s disease, the treatment primarily involves addressing the deficiency of von Willebrand factor (vWF), which is essential for platelet adhesion and stabilization during the clotting process. While various factors play roles in coagulation, Factor 13 is involved in the final stabilization of the fibrin clot, and although its function is crucial in wound healing and maintaining hemostasis, it is not the main factor targeted for treatment in von Willebrand’s disease.

The treatment typically focuses on increasing levels of von Willebrand factor and factor VIII, which is often done through desmopressin administration or infusions of factor concentrates that include vWF. Understanding the specific role of each factor can clarify that while they are all part of the coagulation cascade, not all are directly involved or modified in the management strategies for von Willebrand's disease.